论文部分内容阅读
目的观察慢性心力衰竭患者应用卡维地洛治疗后核因子-κB(nuclear factor-κB,NF-κB)及诱导型一氧化氮合酶(inducible nitric oxide synthase,iNOS)水平的变化。方法 90例慢性心力衰竭患者随机分为常规治疗组和卡维地洛组各45例,采用荧光定量PCR法和酶联免疫分析方法分别检测2组治疗前及治疗12周后血液NF-κB和iNOS水平,测定左室射血分数,并进行6min步行试验。结果治疗12周后,卡维地洛组患者较常规治疗组血液中NF-κB及iNOS水平下降(P<0.05),6min步行距离增加(P<0.05),左室射血分数提高(P<0.05)。结论卡维地洛可能通过抑制慢性心力衰竭患者炎性因子的表达而改善心功能。
Objective To observe the changes of nuclear factor-κB (NF-κB) and inducible nitric oxide synthase (iNOS) in patients with chronic heart failure treated with carvedilol. Methods Ninety patients with chronic heart failure were randomly divided into routine treatment group and carvedilol group, 45 cases each. Fluorescent quantitative PCR and enzyme-linked immunosorbent assay were used to detect the levels of NF-κB, iNOS levels, left ventricular ejection fraction, and 6min walking test. Results After 12 weeks of treatment, the levels of NF-κB and iNOS in the carvedilol group were significantly lower than those in the conventional treatment group (P <0.05), and the distance traveled at 6 minutes increased (P <0.05) and the left ventricular ejection fraction increased (P < 0.05). Conclusion Carvedilol may improve cardiac function by inhibiting the expression of inflammatory cytokines in patients with chronic heart failure.